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Staphylococcus aureus is a leading cause of bacterial infections globally in both
healthcare and community settings. The success of this bacterium is the product of an
expansive repertoire of virulence factors in combination with acquired antibiotic
resistance and propensity for biofilm formation. S. aureus leverages these factors to
adapt to and subvert the host immune response. With the burgeoning field of
immunometabolism, it has become clear that the metabolic program of leukocytes
dictates their inflammatory status and overall effectiveness in clearing an infection. The
metabolic flexibility of S. aureus offers an inherent means by which the pathogen could
manipulate the infection milieu to promote its survival. The exact metabolic pathways that
S. aureus influences in leukocytes are not entirely understood, and more work is needed
to understand how S. aureus co-opts leukocyte metabolism to gain an advantage. In this
review, we discuss the current knowledge concerning how metabolic biases dictate the
pro- vs. anti-inflammatory attributes of various innate immune populations, how S.
aureus metabolism influences leukocyte activation, and compare this with other
bacterial pathogens. A better understanding of the metabolic crosstalk between S.
aureus and leukocytes may unveil novel therapeutic strategies to combat these
devastating infections.
Keywords: Staphylococcus aureus, biofilm, immunometabolism, macrophage, myeloid-derived suppressor
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INTRODUCTION
Staphylococcus aureus (S. aureus) is an opportunistic pathogen that colonizes approximately one-
third of the human population and can cause invasive disease at an array of different sites
throughout the body, including endocarditis, skin and soft tissue infection, bacteremia,
pneumonia, osteomyelitis, and medical implant-associated infection (1, 2). The ability to
successfully infect and persist in such a wide range of tissue niches is due to a number of
characteristics that allow the bacterium to evade immune-mediated clearance. Such attributes
include the production of various toxins, the acquisition of antibiotic resistance or tolerance, and the
ability to form biofilm (3–6). Each of these factors, often in combination with one another,
contribute to the ability of S. aureus to counteract immune effector mechanisms.
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Throughout the course of an infection, both host and
pathogen undergo substantial changes in their metabolic
programs to facilitate the production of different effector
molecules that aid in their respective goals (7, 8). In the case of
leukocytes, this takes the form of regulating the production of
cytokines, such as IL-1b . For S. aureus , metabolic
reprogramming allows for the production of various
leukocidins and lactate, among other virulence factors, that
combat the immune system (9). As an infection progresses,
nutrient concentrations within the tissue milieu can rapidly
fluctuate as host and pathogen compete for the same
extracellular energy sources (10, 11). The intrinsic metabolic
flexibility of S. aureus allows it to quickly adapt to these evolving
conditions to promote its survival (12, 13). While S. aureus may
be able to overcome the depletion of specific nutrient sources, the
leukocyte population may not be as flexible. As metabolism is
inextricably linked to immune cell function, the intentional
depletion and/or release of specific metabolites that can impair
leukocyte microbicidal activity could represent a system by
which the bacteria influences host cell metabolism to its
benefit. Here we provide an overview of how S. aureus
interacts with leukocytes at the metabolic level. We will focus
on immunomodulatory metabolites and how they contribute to
the crosstalk between host and pathogen during an infection,
with a particular emphasis on S. aureus biofilm formation. We
also provide examples of metabolic crosstalk between leukocytes
and other bacterial species as further mechanisms to consider in
the context of S. aureus infection.
IMMUNOMETABOLISM
The study of immunometabolism is focused on linking changes
in metabolic programs to effector functions. Over the years, it has
become apparent that activated leukocytes experience a shift in
metabolism that regulates inflammatory mediator production
(14–16). Activation usually coincides with a metabolic shift from
the energy (ATP)-rich resting state to an increase in the
production of effector metabolites necessary for biosynthetic
processes for inflammatory effector function, such as fatty acid
biosynthesis for prostaglandin production (Figure 1) (17–20).
Since this observation was made, there has been considerable
interest in defining metabolic programs that are characteristic of
either the pro- or anti-inflammatory status of various leukocyte
populations. Much of this fervor originated from the idea that
immune cell function could potentially be orchestrated via the
manipulation of the nutrient milieu or by therapeutically
targeting specific metabolic pathways.
In the context of an infection, immunometabolism is only half
of the story, since pathogens must also acquire essential nutrient
sources for their survival (21). This leads to direct competition
between the host and pathogen on a metabolic scale. Much like
responding leukocytes, S. aureusmust also undergo some degree
of metabolic adaptation to counteract the effects of the immune
response. Switching between alternative forms of metabolism is
common in S. aureus due to its significant degree of metabolic
plasticity (22–24). This flexibility greatly increases the chances
that the bacteria will win the battle of attrition between host and
FIGURE 1 | Metabolic shifts in leukocytes define resting from inflammatory states. Immune cells normally respire under resting conditions to provide sufficient energy
(ATP) for survival. Upon activation, although energy production is somewhat increased, a significant portion of the metabolic flow is dedicated to producing metabolic
intermediates (Effector Metabolites) that are used to generate inflammatory mediators (i.e. cytokines, inflammatory lipids, etc.) to promote leukocyte effector functions
(Immune Response). S. aureus, either through competition for metabolic resources or by releasing immunomodulatory metabolites, can interfere with this process to
disrupt a productive immune response. Monocyte (MO), macrophage (Mj), neutrophil (PMN), and granulocytic myeloid-derived suppressor cell (G-MDSC). Figure
created with BioRender.
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pathogen for specific nutrient sources. If this ability to shift
between different metabolic modes is compromised, it could
drastically alter the landscape of an infection. For instance, work
from our laboratory has established that S. aureus biofilm skews
leukocytes towards an anti-inflammatory phenotype in a murine
model of prosthetic joint infection (PJI) that is mediated, in part,
by IL-10 production (25–28). Recent work demonstrated that the
loss of an essential metabolic process in S. aureus, such as ATP
synthesis (DatpA), significantly decreased the chronicity of
biofilm infection by eliciting a heightened pro-inflammatory
response (29). This is likely attributable to the respiratory
defect in S. aureus DatpA that limits the energy required for
virulence factor production (30), which subsequently led to
increased leukocyte viability and pro-inflammatory activity
(29). Another group has shown that metabolic adaptation of
Pseudomonas aeruginosa is essential for establishing chronic
biofilm infection in patients with debilitating diseases such as
cystic fibrosis (CF). Host-adapted P. aeruginosa strains
preferentially utilized the tricarboxylic acid (TCA) cycle to
limit stress from reactive oxygen species (ROS) produced by
leukocytes in the airway. This TCA metabolic bias in P.
aeruginosa enhanced biofilm formation, which served to
increase the chronicity of infection (31). How metabolic
changes can influence the function of various leukocyte
populations and an overview of critical S. aureus metabolic
pathways in the host will be discussed in the following sections.
MACROPHAGE METABOLISM
The macrophage is currently the prototypical cell studied in the
immunometabolism field. Much progress has been made in
characterizing how macrophages shift their metabolism after
exposure to various stimuli in vitro and how this influences
their effector functions. These experiments led to the discovery
that pro- and anti-inflammatory polarized macrophages have
distinct metabolic programs (32–34). For example, exposure to
Toll-like receptor (TLR) agonists such as bacterial lipoproteins,
peptidoglycan, DNA, or lipopolysaccharide (LPS) biases
macrophages towards glycolysis. In contrast, anti-inflammatory
cytokines (i.e. IL-4 or IL-10) or growth factors promote oxidative
phosphorylation (35, 36). In pro-inflammatory macrophages, the
increase in glycolytic metabolism following TLR activation is due,
in part, to two TCA cycle blocks (Figure 2) (15, 35). These break
points create an anaplerotic cycle that leads to the progressive
accumulation of metabolites such as succinate and aconitate,
which are immunomodulatory in nature. Initial experiments
showed that the intracellular concentration of succinate
dramatically increases following TLR stimulation (37–39). Early
work into understanding metabolic reprogramming found that
this succinate pool was diverted from normal TCA cycle
metabolism and oxidized by succinate dehydrogenase (SDH) to
produce high amounts of ROS, which stabilized the transcription
factor hypoxia-inducible factor-1a (HIF-1a) by preventing its
FIGURE 2 | Macrophage metabolic remodeling during an immune response. Following Toll-like receptor (TLR) activation, macrophages undergo metabolic rewiring
to promote inflammatory mediator production. The TCA cycle breaks at two points, isocitrate dehydrogenase (IDH) that causes the accumulation of aconitate, which
is converted by immune responsive gene 1 (IRG1) to form itaconate, and succinate dehydrogenase (SDH) that leads to succinate accumulation. While this process
normally augments proinflammatory activity, excess itaconate production eventually causes a shift to promote the expression of anti-inflammatory genes. Figure
created with BioRender.
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ubiquitination and degradation (40–44). HIF-1a stabilization
leads to the production of pro-IL-1b, which is cleaved into its
mature form by the NOD-like receptor pyrin domain containing 3
(NLRP3) inflammasome (45–47). A secondary effect of this
process is the HIF-1a-dependent induction of glycolytic
enzymes by that feed back to promote biosynthetic pathways to
augment pro-inflammatory activity (40, 48, 49). Increased
glycolysis serves to produce ATP and sustain the mitochondrial
membrane potential that is necessary for succinate oxidation.
In macrophages, NLRP3 inflammasome activation generally
occurs via a two signal model (45). Signal 1 is mediated by TLR,
IL-1R, or TNFR activation that elicits maximal expression of
pro-IL-1b and inflammasome components. Numerous stimuli
have been shown to provide signal 2 and the diverse structure of
these molecules has led to the concept that cellular stress is a
unifying factor responsible for NLRP3 inflammasome activation
(45). With regard to S. aureus, a-toxin acts as signal 2 to activate
a primed NLRP3 inflammasome (50). This has been attributed to
K+ efflux from cells as a consequence of toxin-mediated
membrane disruption, which can be potentiated by gasdermin
D cleavage by the NLRP3 inflammasome that forms another
transmembrane pore leading to pyroptosis (51). However, in vivo
studies have shown that a-toxin alone is not sufficient for NLRP3
activation. Another requisite is S. aureus lipoproteins that
provide signal 1 via TLR2 activation to elicit maximal
expression of pro-IL-1b and inflammasome components (52).
Recently, it was shown that S. aureus packages its pore-forming
toxins into extracellular vesicles that are then internalized by
immune cells. Upon uptake, S. aureus-derived vesicles contain all
of the requisite factors to induce inflammasome activation, thus
providing the bacteria with another mechanism to modulate the
immune response (53). A paradox is why S. aureus augments
NLRP3 inflammasome activation given its ability to produce the
pro-inflammatory cytokines IL-1b and IL-18. However, a recent
study has demonstrated that S. aureus a-toxin exploits NLRP3
inflammasome activation in macrophages by recruiting
mitochondria away from the phagosome, which inhibits
mitochondrial ROS production via complex II (SDH) of the
electron transport chain (ETC), phagosomal acidification, and
bacterial killing (54). This effect was independent of NLRP3-
mediated IL-1b and IL-18 production. Intriguingly, this
represents another mechanism that S. aureus exploits to
prevent immune-mediated clearance.
Subsequent in vitro studies examining the mechanisms of
macrophage metabolic remodeling revealed that the increase in
succinate following TLR activation was due to the action of
itaconate, a derivative of the TCA intermediate aconitate.
Itaconate is produced by immune-responsive gene 1 (IRG1)
and as the concentration of itaconate increases, SDH is
progressively inhibited. This leads to succinate accumulation
and decreased oxygen consumption via the inhibition of SDH,
which is also complex II of the mitochondrial ETC (Figure 2)
(55–59). Although the initial production of itaconate augments
macrophage pro-inflammatory activity, its accumulation begins
to exert anti-inflammatory effects (60). As itaconate accumulates,
it is transported out of mitochondria where it can interact with
cytoplasmic protein targets, namely Kelch-like ECH-associated
protein 1 (KEAP1) (61–63). Under homeostatic conditions,
KEAP1 is bound to nuclear factor erythroid 2-related factor 2
(Nrf2), which targets the complex for proteasomal degradation.
Under stress conditions, such as S. aureus-induced toxin action,
the complex dissociates and Nrf2 translocates to the nucleus
where it acts as a transcription factor for numerous anti-
inflammatory genes (64). Itaconate is capable of disrupting the
KEAP1-Nrf2 association via alkylation of cysteine residues in
KEAP1 to promote Nrf2 nuclear translocation and the
transcriptional activation of anti-inflammatory genes. Via this
mechanism, itaconate represents a way to counterbalance the
proinflammatory activity of succinate accumulation (65, 66).
Amino acid metabolism is also important for influencing
macrophage polarization, where arginine is differentially utilized
by macrophages to exert distinct effector functions (67). For
example, in response to planktonic S. aureus and other pro-
inflammatory stimuli, macrophages utilize arginine to drive
inducible nitric oxide synthase (iNOS) activity and nitric oxide
(NO) production (68). Nitric oxide is a highly reactive free
radical that exerts potential bactericidal activity by inducing
DNA and membrane damage as well as targeting oxidative
metabolism (69–71). However, S. aureus is capable of evading
host NO production, which differentiates it from other
Staphylococcal species. One example is flavohemoprotein
(hmp) expression that allows S. aureus to detoxify its
environment by converting NO into nitrate, making it an
iNOS-dependent virulence determinant (72). Another
component of the nitrosative stress response in S. aureus is L-
lactate dehydrogenase (ldh1), which is a NO-inducible gene.
While hmp serves to detoxify the environment, Ldh allows S.
aureus to maintain redox homeostasis by promoting the
conversion of pyruvate to lactate (73). Although this metabolic
program generates less ATP compared to oxidative metabolism,
it provides a mechanism by which S. aureus can maintain its
reducing equivalents until Hmp can decrease NO levels. In
contrast to iNOS, arginine is used by arginase-1 (Arg-1) in
anti-inflammatory polarized macrophages to produce
ornithine. Ornithine is further metabolized into polyamines
and proline for wound repair and cell growth processes (74,
75). Increased Arg1 expression has been linked to macrophage
anti-inflammatory activity during S. aureus biofilm infection
(76–78). To determine if Arg1 expression was required for the
immune suppression associated with S. aureus biofilm infection,
our laboratory utilized Arg-1fl/fl; Tie-2Cre conditional knockout
mice where myeloid cells lacked Arg-1. Arg1 was dispensable for
myeloid immunosuppression during biofilm formation but was
critical for S. aureus containment during abscess formation (79).
This was in agreement with a prior study showing that host
polyamine production was important for controlling S. aureus
growth in a mouse SSTI model (80). Taken together, these results
indicate that the effects of Arg1 expression are context-dependent
in terms of myeloid cell function during S. aureus biofilm vs.
planktonic infection.
Monocyte/macrophage metabolism was recently shown by
our laboratory to be important for influencing the outcome of S.
Horn and Kielian Host-Pathogen Metabolic Crosstalk
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aureus biofilm infection in a mouse model of PJI (81). S. aureus
biofilm biased monocytes towards oxidative metabolism which,
much like macrophages exposed to biofilm in vitro, were largely
anti-inflammatory in nature (82). Therefore, a nanoparticle
approach was used to deliver oligomycin, an inhibitor of
complex V of the ETC, to redirect monocyte metabolism
towards glycolysis. Oligomycin nanoparticles augmented
monocyte pro-inflammatory activity, which coincided with
reduced biofilm burden in vivo, indicating that metabolic
remodeling could prove to be an effective therapeutic approach
for chronic biofilm infection (81). Importantly, monocyte
metabolic reprogramming was capable of attenuating an
established biofilm infection, whose efficacy was heightened by
concominant antibiotic treatment.
GRANULOCYTE METABOLISM
Although much progress has been made in understanding the
role of metabolism in macrophages, comparatively less is known
about how metabolic changes affect granulocyte function.
Neutrophils have been shown to rely almost entirely on
glycolytic modes of metabolism to fuel their effector functions,
which agrees with a reduced mitochondrial abundance (83, 84).
Similar to pro-inflammatory macrophages, activated neutrophils
adopt a metabolic program that is similar to the aerobic
glycolysis that was first described by Otto Warburg in the
1920’s (85), which has since become known as “Warburg
metabolism” (86, 87). This heavy reliance on glycolysis, even in
oxygen replete conditions, is necessary to increase carbon
flux through the pentose phosphate pathway (PPP) to increase
the NADPH pool that is required for NADPH oxidase activity
and ROS production (16, 88). Like pro-inflammatory
macrophages, metabolic intermediates from the TCA cycle
that is fueled by glycolysis, are used for anabolic processes to
promote granulocyte functional activity. For example, citrate
from the TCA cycle can be diverted for fatty acid synthesis to
drive the production of pro-inflammatory mediators such as
prostaglandins and leukotrienes (89–92). Although granulocytes
are typically considered as purely glycolytic, some studies have
also identified granulocytes that instead utilize mitochondrial
oxidative metabolism (93). In the context of cancer, glucose
within the tumor microenvironment can quickly become a
limiting factor. Under these conditions, a population of
immature, c-Kit+ neutrophils has been shown to utilize
fatty acid oxidation to maintain ROS production by NADPH
oxidase (93). These immature neutrophils in tumor-bearing mice
were regulated through aberrant SCF/c-Kit signaling and
metabolically adapted for the lack of glucose within the tumor
microenvironment. Functionally, this meant the adapted
neutrophils retained the ability to produce ROS, which can
interfere with CD4+ T cell anti-tumor activities (94–96).
Although not definitively established, these c-Kit+ neutrophils
possess many characteristics of granulocytic MDSCs (G-MDSCs,
see below). A similar reduction in glucose availability occurs
during S. aureus biofilm formation, as reflected by a shift towards
fermentative metabolism and lactate production (23), which
shapes the metabolic attributes of infiltrating leukocytes, which
is discussed below.
MDSCs are a heterogenous population of immature myeloid
cells that are grouped into two categories based on their shared
characteristics with mature monocytes or neutrophils, namely
M-MDSCs and G-/PMN-MDSCs (97–99). Both subsets are
thought to exert their suppressive activity through increased
ROS production, although M-MDSCs can also utilize Arg-1 to
deplete arginine that is required for TCR expression to
inhibit T cell activation (94, 100, 101). Although MDSCs
have been best characterized in cancer, they have also been
implicated in promoting chronic infection, including S. aureus
biofilm (25–28), bone, and skin infection (102, 103). Due to
the extensive heterogeneity of MDSCs and context-dependent
modes of action, describing a singular metabolic program that is
characteristic of these cells has proved challenging. Nevertheless,
a few reports have examined MDSC metabolism and how
this affects their suppressive activity (104–106). One study
found that M-MDSCs suppress T cell activation by inhibiting
glycolysis through direct physical contact. Interestingly,
M-MDSCs were metabolically dormant, characterized by
an accumulation of the a-dicarbonyl methylglyoxal.
Methylglyoxal was found in T cells following co-culture with
M-MDSCs and treatment with dimethylbiguanide (DMBG),
which neutralizes dicarbonyls, restored T cell activation,
supporting the importance of methylglyoxal in MDSC-
mediated T cell suppression (107, 108). Another study
has pointed to fatty acid accumulation and subsequent
prostaglandin production as a metabolic mechanism for
MDSC suppression. Specifically, PMN-MDSCs overexpress a
fatty acid transporter (FATP2), which led to fatty acid
accumulation and prostaglandin E2 (PGE2) production that
promoted their immunosuppressive effects (109). These studies
highlight the metabolic diversity that MDSCs can adopt to
influence their inhibitory activity. S. aureus biofilm elicits G-
MDSCs that may utilize a distinct metabolic program to exert
their suppressive effects than those described here, which
remains to be determined. Further investigation into how
MDSC metabolism evolves throughout the course of infection
is required to appreciate the role that these cells play in shaping
the host immune response.
HOST–PATHOGEN METABOLIC
CROSSTALK
In an infectious milieu, not only will leukocytes and the pathogen
have to compete for the same nutrient sources, but this also
creates a new environment in which the two could interact. For
instance, a recent study demonstrated how host adapted strains
of P. aeruginosa responded to the secretion of itaconate by
selecting for variants that were able to utilize the host-derived
metabolite as a nutrient source (110). This selection process
coincided with modifications of membrane structural
components in P. aeruginosa to augment host-derived
Horn and Kielian Host-Pathogen Metabolic Crosstalk
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itaconate release, thereby establishing a positive feedback loop to
promote chronic infection. This illustrates the importance of not
only considering the metabolism of either the host or pathogen
in isolation, but also the byproducts that they excrete and
exchange. Such molecules constitute a new avenue for cellular
signaling that the host and/or pathogen could leverage to their
benefit during infection. These systems become even more
complex in the context of polymicrobial infections, a common
occurrence with P. aeruginosa and S. aureus in the lungs of CF
patients (111–113). With the additional layering of another
organism, the potential number of molecules and interactions
increases exponentially.
S. AUREUS METABOLISM AND
COMPETITION FOR NUTRIENTS
Competition for the various nutrient sources in an infectious
milieu is probably the most intuitive level by which metabolic
crosstalk occurs. In an infection, there are at least two entities (i.e.
host and pathogen) racing to consume the same resources, which
becomes more complicated in the context of polymicrobial
infections. Glucose and oxygen are among the first resources
that become restricted in these settings and their deprivation can
be enough to bias the actions of responding immune cells or
pathogens alike. These events can also dictate the nature of
immune cell death, which has been reported to occur via two
types of programmed necrosis, namely necroptosis or pyroptosis.
Necroptosis is induced by the interaction of TNF with receptor-
interacting protein kinase 1 (RIPK1), eliciting a cascade that
culminates in the phosphorylation of mixed lineage kinase
domain-like protein (MLKL) that damages the plasma
membrane leading to cell death. Pyroptosis occurs in response
to inflammasome activation that cleaves gasdermin D, which
oligomerizes to form pores in the cell membrane. While both
forms of cell death induce inflammation, the heightened
production of inflammatory mediators associated with
inflammasome activation makes pyroptosis more inflammatory
in nature than necroptosis (114). The roles of S. aureus
metabolism in dictating different modes of immune cell death
will be discussed below.
CARBOHYDRATE AVAILABILITY AND S.
AUREUS METABOLISM
Much work has been done to elucidate S. aureus metabolic
adaptations under a variety of in vitro and in vivo conditions
and the reader is directed to several excellent and comprehensive
reviews on the topic (9, 23, 24), since only a brief overview is
provided here. S. aureus utilizes a number of two-component
regulatory systems to sense changes in its environment (115,
116). These systems interface with complex transcriptional
networks to tightly control nutrient use throughout different
phases of growth and infection. This is referred to as carbon
catabolite repression and ensures that bacteria optimally utilize
available nutrient resources in a hierarchical manner (117–119).
S. aureus uses two catabolite control proteins (CcpA & CcpE) to
modulate glucose utilization through central carbon metabolism.
In glucose replete conditions, oxidative metabolism is repressed
by CcpA, which inhibits the expression of critical TCA cycle
enzymes (120–122). As glucose becomes depleted, CcpA activity
is reduced which induces the TCA cycle and citrate production.
Citrate is sensed by CcpE, which bolsters TCA cycle activity and
increases the expression of S. aureus virulence factors (123, 124).
It has been shown that S. aureus can quickly outcompete host
keratinocytes for available glucose, which leads to keratinocyte
death by pyroptosis (125, 126). Pyroptosis fails to clear S. aureus
infection because NLPR3 inflammasome activation by a-
hemolysin redirects mitochondria away from bacteria-
containing phagosomes, thereby preventing acidification and
killing (54). Thus, pyroptosis is beneficial for the bacteria
because it promotes its intracellular escape and dissemination,
while simultaneously introducing any host-derived metabolic
intermediates into the infection milieu to be utilized for pathogen
survival and replication.
The importance of this battle for glucose is particularly
relevant in the setting of diabetes. Diabetic patients are
characterized by hyperglycemia and often present with
persistent and invasive S. aureus infections (127, 128). A recent
study examining S. aureus SSTI in a diabetic mouse model has
shown that although there is more bioavailable glucose in
diabetic tissues, phagocytes failed to take up the carbohydrate
with either GLUT-1 or GLUT-3 transporters. This resulted in
impaired oxidative burst activity and increased bacterial burden
(129). S. aureus infection in diabetic patients has been linked to
an increase in the recruitment of low-density neutrophils (LDNs)
(130). LDNs are associated with increased rates of NETosis, or
the production of neutrophil extracellular traps (NETs).
Although, NETs are typically considered to exert anti-
microbial effects, elevated levels of NETosis have been linked
to impaired wound healing in patients with diabetes, whose
neutrophils are more prone to NET formation (131). Increased
NETosis in diabetic patients could result from the elevated levels
of glucose within diabetic tissues, as glucose is a metabolic
requirement for the process. Of note, MDSCs that are
expanded in the blood of tumor patients have been
characterized as LDNs (132, 133). By extension, it is intruging
to speculate that the LDNs described in diabetic patients are
actually MDSCs, which might explain why these individuals are
more prone to chronic and recurrent S. aureus infections,
although this remains to be determined.
HYPOXIA AND S. AUREUS METABOLISM
Hypoxia is particularly relevant in the context of biofilm
infections, since bacteria in the innermost regions of the biofilm
experience low oxygen bioavailability. Anaerobic conditions have
been shown to induce the expression of biofilm-associated genes
such as icaADBC that encode polysaccharide intercellular
adhesins that promote bacterial aggregation and adherence to
host surfaces (134–136). Bone, a niche that is often targeted by
Horn and Kielian Host-Pathogen Metabolic Crosstalk
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S. aureus biofilm, has a low oxygen tension since it is less
vascularized compared to other tissues (137, 138). The immune
response elicited during S. aureus bone infection exacerbates this
hypoxic environment as infiltrating immune cells quickly increase
their oxygen demand upon activation (139, 140). The biofilm
responds to this progressive decline in oxygen tension by
switching from respiration to fermentation concomitant with an
increase in virulence factor production to attack immune cells to
promote infection persistence (141). The transition from
respiration to fermentation in S. aureus is regulated by several
factors including SrrAB and Rex. The SrrAB two-component
system was initially identified through homology comparisons
with the ResDE two-component system of Bacillus subtilis, which
controls the switch between aerobic and anaerobic respiration
(142). While its ligand remains unknown, SrrAB increases the
expression of fermentative genes such as pflAB, adhE, and nrdDG
that allow it to thrive in an anaerobic environment (141, 143, 144).
S. aureus can also respond to changes in oxygen availability
indirectly through the transcriptional repressor Rex, which
inhibits genes that are important for anaerobic respiration when
oxygen is present. Rex senses redox conditions within the cell
through changes in the NADH/NAD+ pools. As NADH levels
rise, Rex becomes derepressed and is released from the DNA,
thereby allowing for the transcription of fermentative genes in an
effort to maintain reducing equivalents within the cell (9, 145).
Therefore, oxygen depletion could either be a consequence of
bacterial growth, or a strategy enacted by the biofilm to ensure
persistent infection.
EPIGENETIC CHANGES INDUCED BY
IMMUNOMODULATORY METABOLITES
Bacterial-derived metabolites are also capable of affecting
leukocyte activation and function. Recent work has shown that
lactate production by S. aureus biofilm induces epigenetic
changes in leukocytes at the level of histone acetylation (146).
Utilizing a number of S. aureus lactate dehydrogenase (ldh)
mutants, our group demonstrated that biofilm-derived lactate
was imported into MDSCs and macrophages where it inhibited
histone deacetylase 11 (HDAC11; Figure 3). HDAC11 inhibition
prevented its normal function of counterbalancing HDAC6
activity that is a positive regulator of IL-10 transcription,
resulting in enhanced IL-10 production and biofilm
persistence. Synovial fluid from patients with PJI contained
elevated amounts of both D-lactate and IL-10 compared with
control subjects and IL-10 production by human monocyte-
derived macrophages was induced by biofilm-derived lactate,
supporting the translational relevance of these findings (146).
This demonstrates how a bacterial-derived metabolite can
significantly rewire the host-pathogen dynamic to favor
persistent infection. Recently, lactate has also been shown to
directly modify histones with functional genomic implications
(147–149). This lactate modification of histone lysine residues
(termed lactylation) was shown to operate as a sort of “clock”. As
inflammation progressed, the lactate produced by increased
glycolysis lactylated histones. As these lactate marks
accumulated, homeostatic genes were induced that led to a
FIGURE 3 | S. aureus biofilm regulates leukocyte inflammatory activity. S. aureus biofilms employ a number of strategies to create an infection milieu to ensure
persistence. Two of these approaches involve the action of either bacterial-derived metabolites or intrinsic reprogramming of monocyte/macrophage metabolism that
culminate in the expression of anti-inflammatory genes. (Top) Biofilm augments oxidative metabolism in infiltrating monocytes and macrophages that biases them
towards an anti-inflammatory phenotype. (Bottom) In MDSCs and macrophages, biofilm-derived lactate causes epigenomic remodeling that leads to an increase in
IL-10 expression. Figure created with BioRender.
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resolution of inflammation. Thus, histone lactylation functions
as an endogenous timer for inflammatory events.
While innate immune cells do not possess the characteristic
long-lasting immunity of lymphocytes, they are capable of trained
immune memory (150, 151). Trained immunity arises from
epigenetic modifications that prime leukocytes for a subsequent
encounter with another stimulus (152–154). Interestingly, trained
immunity is not stimulus-specific and can induce widespread
changes in how a leukocyte responds to a second insult. Several
studies have shown that prior infection with S. aureus establishes
trained immunity in macrophages that provides temporary
protection from a second bacterial challenge (155–157). Trained
immunity in response to S. aureus has been shown to occur via
epigenetic changes induced by the metabolite fumarate. Fumarate,
like lactate, interferes with the epigenomic remodeling of histone
marks by acting as an antagonist for lysine demethylases (KDMs)
(158–162). A recent study demonstrated the importance of fumarate
during S. aureus infection by contrasting wild type infection with
DhemB small colony variants (SCVs) that were able to deplete local
fumarate stores via enhanced fumarate hydratase (fumC) expression
(163, 164). Trained immunity was assessed by comparing bacterial
burden after a secondary challenge with S. aureus 28 days following
the primary infection. The reduction in fumarate by SCVs increased
host cell glycolysis, which inhibited trained immunity by
necroptosis (Figure 4) rather than inflammasome-dependent
pyroptosis (165). This is beneficial for bacterial persistence since
necroptosis elicits less inflammation compared to pyroptosis (166).
These effects were not observed with wild type S. aureus, which was
less effective at utilizing fumarate. This difference may represent one
explanation for why S. aureus SCVs are typically associated with
chronic infections.
MODULATING METABOLISM AS A
THERAPEUTIC TARGET
The selective targeting of either host or pathogen metabolism
represents an exciting therapeutic prospect that would bolster
traditional antibiotic therapies that are commonly used for
infections. Metabolic interventions have the potential to be
highly efficacious as was shown in our work where metabolically
reprogramming monocytes synergized with antibiotics to reduce
established S. aureus biofilm infection to below the limit of
detection (81). Of particular interest are therapies targeting
FIGURE 4 | S. aureus small colony variants (SCVs) interfere with the establishment of trained immunity. The generation of SCVs with mutations in metabolic
pathways exert influence over the formation of trained immunity. S. aureus SCVs with hyperactive fumarate hydratase (fumC) quickly degrade mitochondrial pools of
fumarate, which leads to an upregulation of glycolysis and impaired formation of trained immunity. The absence of fumuarate causes KDM5 to become active, which
removes the methylation marks around the promoters of pro-inflammatory genes, thereby decreasing the accessilibity of the chromatin in these regions. Figure
created with BioRender.
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immunometabolism rather than bacterial metabolism, since
pathogen resistance would be less prevalent with a host-targeted
approach. If we can gain a better understanding of the underlying
metabolic modules that dictate beneficial vs. detrimental immune
responses, then it should be feasible to tailor leukocyte metabolism
to enhance pathogen neutralization. The main caveat of this
approach is that the metabolic pathways utilized by the host and
pathogens share many attributes. Therefore, potential metabolic
therapies would need to be targeted to avoid non-specific effects.
CONCLUSION AND FUTURE DIRECTIONS
In a time of increasing interest in leukocyte metabolism, it is
important to think globally in terms of the interplay between
host and pathogen metabolic states. Bacterial pathogens, such as
S. aureus, undergo their own metabolic programming (10, 11),
often in direct competition with responding immune cells. In
addition, the metabolic attributes of tissue resident parenchymal
cells have the potential to shape the metabolic responses of both
infiltrating leukocytes and bacteria, revealing another level of
complexity. Considerable care must be taken when designing
experiments to deconstruct these complex systems in vitro, since
the composition of mammalian cell culture media can have
drastic deviations from metabolite concentrations found in
human plasma (167). Therefore, findings must be validated
in leukocytes and bacteria immediately ex vivo, as the selection
of in vitro culture conditions could result in metabolic changes
that are not reflective of in vivo infection (167).
As discussed in this review, S. aureus as well as other bacterial
pathogens possess the ability to not only modify their
metabolism, but also that of the host. Further work is needed
to understand the numerous intricacies that underpin
metabolism, especially in the context of an infection where
multiple players are involved. Fortunately, the field is
advancing rapidly with the development of novel tools and
methods to dissect metabolism with single cell resolution (168,
169). The continued development of these technologies will be
integral for future studies. Should these efforts be successful,
metabolic modulation could advance therapeutic approaches for
S. aureus infection in combination with conventional antibiotic
treatment regimens.
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